Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5919)	11/11/1998 8:39:00 PM
From: Bob L	Respond to of 9719

Not being a $100 target sort of guy, I was looking at the option idea as well. However, its a mighty thin market for CLTR options, with about zilch for open interest. This seems surprising since, as you say, the stock has been quite volatile lately and not everybody is as confident as V1.

To: Rocketman who wrote (5919)	11/12/1998 9:09:00 AM
From: bluejeans	Read Replies (1) \| Respond to of 9719

Looks like someone's short may pay off fast. interactive.wsj.com Last February, EntreMed Inc., a tiny biotech company that licensed the two biological agents, hired Harvard cell biologist Bjorn Olsen to look into endostatin. Using endostatin variants he made, he couldn't reproduce Dr. Folkman's results, Dr. Olsen says.